Free tool · No account
Clinical trials for lymphoma
Lymphoma trials divide sharply between Hodgkin and the many non-Hodgkin subtypes, and between newly diagnosed and relapsed disease. The specific subtype is the most useful thing to include.
1,657 recruiting trials. Showing a sample.
- recruitingNCT07070648
Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET
This is a prospective, multicenter, multi-cohort study of ctDNA combined with PET for predicting the efficacy of standard first-line therapy for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
Listed by the study for Diffuse Large B-Cell Lymphoma. Record updated 2025-07-17.
Sponsored by Fudan UniversityFull details on ClinicalTrials.gov → - recruitingPhase 1NCT05581030
CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
The purpose of the study is to evaluate the safety and tolerability of the study drug, calaspargase pegol, when given with multi-agent chemotherapy.
Listed by the study for Precursor Cell Lymphoblastic Leukemia-Lymphoma. Record updated 2026-03-06.
Sponsored by H. Lee Moffitt Cancer Center and Research InstituteFull details on ClinicalTrials.gov → - recruitingPhase 2NCT06931652
Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab
The purpose of this phase 2 study is to evaluate the efficacy and safety of epcoritamab in subjects with relapsed or refractory primary diffuse large B-cell lymphoma of the Central Nervous System treated with rituximab and lenalidomide.
Listed by the study for Primary CNS Lymphoma (PCNSL). Record updated 2026-06-15.
Sponsored by The Lymphoma Academic Research OrganisationFull details on ClinicalTrials.gov → - recruitingPhase 1, Phase 2NCT06375733
A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL
This is a multicentre, open-label phase Ib/II study. The purpose of the study is to assess the safety and efficacy of GFH009 in combination with Zanubrutinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Listed by the study for Large B-cell Lymphoma. Record updated 2025-08-12.
Sponsored by Genfleet Therapeutics (Shanghai) Inc.Full details on ClinicalTrials.gov → - recruitingPhase 1, Phase 2NCT07123454
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
This is a phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).
Listed by the study for B-cell Non-Hodgkin Lymphoma. Record updated 2026-11-02.
Sponsored by AstraZenecaFull details on ClinicalTrials.gov → - recruitingPhase 2NCT06854159
Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy
This phase II trial tests how well odronextamab works before and after standard of care (SOC) chimeric antigen receptor (CAR) T-cell therapy in treating patients with diffuse large B-cell lymphoma (DLBCL) that has come back after a period of improvement (relapsed) or that has ...
Listed by the study for Recurrent Diffuse Large B-Cell Lymphoma. Record updated 2026-07-08.
Sponsored by University of California, DavisFull details on ClinicalTrials.gov → - recruitingNCT06781359
Study on Plasmablastic Lymphoma Patients
This is an observational, multicenter, international and retrospective study, that aims to collect data on clinical and pathological characteristics, treatment regimens, outcome, and prognostic factors (clinical, biomarkers and/or radio-metabolic) in patients affected by PBL.
Listed by the study for Plasmablastic Lymphoma. Record updated 2026-08-19.
Sponsored by Fondazione Italiana Linfomi - ETSFull details on ClinicalTrials.gov → - recruitingNCT06550427
Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing
Lymphoma is a prevalent lymphoid malignancy globally and in Taiwan. Large B-cell lymphoma (LBCL) is the most common subtype of aggressive B-cell lymphoma. LBCL's aggressive nature manifests through extranodal involvement, severe symptoms, and relative refractoriness to therapi...
Listed by the study for Lymphoma. Record updated 2025-06-17.
Sponsored by National Taiwan University HospitalFull details on ClinicalTrials.gov → - recruitingPhase 1NCT07072169
A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, as well as preliminary efficacy of mRNA encoding CD19/CD3 T cell engager (ABO2203) in adult patients with relapsed or refractory CD19-positive B-NHL, This study included dose...
Listed by the study for B-cell Non-Hodgkin Lymphoma. Record updated 2025-07-18.
Sponsored by Ruijin HospitalFull details on ClinicalTrials.gov → - recruitingPhase 1NCT07137494
A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)
This study will test whether MB-CART19.1 is a safe and effective treatment for central nervous system lymphoma (CNSL). This study will test different doses of MB-CART19.1 to find the highest dose that causes few or mild side effects in participants.
Listed by the study for Primary Central Nervous System (CNS) Lymphoma. Record updated 2026-06-05.
Sponsored by Memorial Sloan Kettering Cancer CenterFull details on ClinicalTrials.gov →
Data from ClinicalTrials.gov, retrieved 2026-11-14. Study sponsors write and update their own records there, including the recruitment status shown here, and the U.S. government does not review or approve every study listed. A trial showing up here is not a recommendation and not a determination that anyone qualifies. Eligibility is decided by the trial's own doctors.
Refine for your situation
Add whatever you know: an age, a city, a mutation from a pathology report. We'll narrow the list to trials that fit. Describe it in your own words.
Trials for other conditions
What we will never do with your records
This generator runs without an account, and KeptWell itself makes the same promises to every family, regardless of plan or price.
- We won't sell your data.
- Not to advertisers, not to data brokers, not to insurers, not to pharma, not to anyone, in any form, ever.
- We won't train AI models on your records.
- KeptWell does not opt in to model training. OpenAI and Anthropic do not use API inputs or outputs to train their models by default.
- We won't lock you in.
- You can export everything in your circle as a ZIP at any time. Cancellation is one click.
Common questions
- Is this lymphoma trial finder really free?
- Yes. You describe the situation, we search ClinicalTrials.gov and show what matches. No account, no payment, no email required. Nothing you type is saved.
- Does showing up here mean the patient qualifies?
- No. A listing here is not a recommendation, and the U.S. government does not review or approve every study on ClinicalTrials.gov. These are trials worth asking your care team about. Every trial has detailed eligibility criteria that the trial's own doctors evaluate, and many depend on test results and treatment history that only your medical team knows in full.
- How current is this list?
- The trials come directly from ClinicalTrials.gov and are refreshed daily, with the retrieval date shown under the list. Each study record is written and kept up to date by that study's own sponsor, so the recruitment status is what the sponsor last reported. Each result links to the full, live record, and the finder above always runs a fresh search when you use it.
- What should I do with a trial that looks promising?
- Bring it to your oncologist or care team, and mention the NCT number (the ID that starts with NCT). They can tell you whether it is a genuine fit and refer you to the trial site.
Found trials worth discussing? Keep them next to the records.
The next step is a conversation with the care team, and that goes better when the scans, labs, and trial details live in one place everyone in the family can see. That's what KeptWell is: the binder, but it understands what's inside.
Get started
We'll email you a secure sign-in link. It works whether you're new here or already have an account.